Generic Name and Formulations:
Cimetidine 300mg, 400mg; tabs.
Prestige Brands, Inc.
Indications for TAGAMET:
Active duodenal or benign gastric ulcer. Maintenance of healed duodenal ulcers. Pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome). GERD.
Active duodenal ulcer: 800mg at bedtime for 4–8 weeks. Maintenance: 400mg at bedtime. Active benign gastric ulcer: 800mg at bedtime or 300mg 4 times daily with meals and at bedtime for 6 weeks. Hypersecretory conditions: 300mg 4 times daily with meals and at bedtime; max 2.4g/day. GERD: 800mg 2 times daily or 400mg 4 times daily for max 12 weeks; see full labeling. For difficult to heal ulcers: see full labeling.
<16 yrs: not recommended; see full labeling. Doses of 20–40mg/kg per day have been used.
Impaired renal or hepatic function. Elderly. Debilitated. Immunocompromised. Pregnancy (Cat.B). Nursing mothers: not recommended.
Avoid antacids within 1 hour of dosing. May potentiate anticoagulants, phenytoin, theophylline, lidocaine, and others (see literature) by inhibition of hepatic microsomal enzymes. May alter absorption of drugs affected by gastric pH (e.g., ketoconazole), give 2 hours before cimetidine.
Headache, diarrhea, dizziness, somnolence, CNS disturbances, gynecomastia, rash (maybe serious eg, Stevens-Johnson syndrome); rare: arthralgia, myalgia, blood dyscrasias, nephritis, increased serum transaminases, pancreatitis, bradycardia, tachycardia; increased risk of community-acquired pneumonia (see literature).
Tabs 300mg—100; 400mg—60
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy